Back to Basics: Back to Basics: Endocrinology Endocrinology Diabetes, Obesity and Diabetes, Obesity and Thyroid Thyroid
Jan 11, 2016
Back to Basics: Back to Basics: EndocrinologyEndocrinology
Diabetes, Obesity and Diabetes, Obesity and
ThyroidThyroid
Diagnosis of DiabetesDiagnosis of Diabetes
What are the CDA criteria for the What are the CDA criteria for the diagnosis of diabetes?diagnosis of diabetes?
Who should be screened for type 2 Who should be screened for type 2 diabetesdiabetes
Which type of diabetes has a stronger Which type of diabetes has a stronger genetic component type 1 or type 2?genetic component type 1 or type 2?
Which type of diabetes only presents Which type of diabetes only presents in the elderly population?in the elderly population?
Screening for Type 2 Screening for Type 2 DiabetesDiabetes
5.7-6.9 mmol/L plus risk factor(s) for diabetes/IGT
2hPG in a 75-g OGTT
Every 3 years in individuals 40 years of age Earlier and/or more frequently in individuals with
additional risk factors
FPG
CDA 2003 Clinical Practice Guidelines. Can J Diabetes 2003;27:S11
Definitions of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance
(IGT) and Diabetes
Fas
ting
Glu
cose
(mm
ol/
L)
3.5
4.5
5.5
6.5
7.5
8.5
3 4 6 8 10 12 14
2-h Post-load Glucose (mmol/L)
Diabetes
IFG + IGT
NormalGlucose
IGT
IFG6.1
6.9
7.8 11.1
* 1. ADA Diabetes Care 2006;29(Suppl 1):S47,2. CDA Can J Diabetes 2003;27(Suppl 2):S7, 3.WHO 1999 NDC/NCS.99.2 accessed Mar 2 2006 from www.who.int
5.6*
The World Wide Epidemic:The World Wide Epidemic:Prevalence of DiabetesPrevalence of Diabetes
5%
8%
14%
4%
3%
The Worldwide Epidemic:The Worldwide Epidemic:Diabetes TrendsDiabetes Trends
30
135177
221
300
370
0
50
100
150
200
250
300
350
400
Mil
lion
s w
ith
Dia
bete
s
1985 1995 2000 2010 2025 2030Sources: www.who.intwww.idfZimmet P. et al Nature: 414, 13 Dec 2001
The Diabetes The Diabetes Epidemic Epidemic in Canadain Canada
Prevalence, Risk Factors, Prevalence, Risk Factors,
and and
Current Cost ImplicationsCurrent Cost Implications
The Canadian Epidemic: The Canadian Epidemic: Prevalence in Canada, 1994/95 to Prevalence in Canada, 1994/95 to
2000/01, by Province2000/01, by Province 1996 - 1997
2.53.1
3.23.20
3.203.23.2
3.40
4.60
4.6
Prevalence (%)
1.30 to 2.903.00 to 3.403.50 to 3.90
4.00 to 4.405.00 to 5.405.50 to 5.90No data
3.10
1998 - 1999
3.4
4.4
3.13.13.1
3.33.6
4.0
5.2
3.1
2000 - 2001
1.3
3.43.9
4.0
4.0
4.14.2
5.0
5.1 5.2
5.8
3.2
1994 - 1995
2.7
2.8
2.83.0
3.13.1
3.2
3.50
3.6
3.90
Source: Statistics Canada: CANSIM II
Diabetes Risk Diabetes Risk FactorsFactors
Modifiable Risk FactorsModifiable Risk FactorsPhysical Activity Physical Activity
Obesity Obesity DietDiet
&&
Non-Modifiable Risk FactorsNon-Modifiable Risk FactorsEthnicityEthnicity
Family HistoryFamily History
Diabetes Risk Factors:Diabetes Risk Factors:ModifiableModifiable
0
1
2
Rel
ativ
e Ris
k
>7 4 to 7 2 to 4 .5 to 2 <0.5
Hours per week
Physical Activity: Relative Risk For Developing Diabetes
Source: Choi B, Shi F. Diabetologia 2001, 44:1221-1231.
0
0.5
1
1.5
2
rela
tive
ris
k
5 4 3 2 1quintiles based on fat/fibre content
Healthy Diet: Relative Risk for Developing DM
Source: Choi B, Shi F. Diabetologia 2001, 44:1221-1231.
Diabetes Risk Factors:Diabetes Risk Factors:ModifiableModifiable
0
10
20
30
40
Rela
tive R
isk
<23 23-25 25-30 30-35 <35
BMI = wt/ (ht)2
Obesity: Relative Risk For Developing DM
Source: Choi B, Shi F. Diabetologia 2001, 44:1221-1231.
Diabetes Risk Factors:Diabetes Risk Factors:ModifiableModifiable
Relative risk for developing type 2 is Relative risk for developing type 2 is cumulative.cumulative. A physically inactive individual (less than 30 A physically inactive individual (less than 30
min/wk of exercise) min/wk of exercise) who consumes an unhealthy dietwho consumes an unhealthy diet and is modestly overweight (BMI 25-30) and is modestly overweight (BMI 25-30) would have a 30-fold increased (1.8*2*8) risk of would have a 30-fold increased (1.8*2*8) risk of
developing type 2 DM compared to the general developing type 2 DM compared to the general population, population,
which would translate to a lifetime risk of which would translate to a lifetime risk of nearly 100%nearly 100%
REF: Atlas of Diabetes 2nd Ed, Part 2, JS Sklyer, EditorREF: Atlas of Diabetes 2nd Ed, Part 2, JS Sklyer, Editor
Diabetes Risk Factors:Diabetes Risk Factors:ModifiableModifiable
Run away from diabetes
The Epidemic: The Epidemic: Non-Modifiable Non-Modifiable
Risk FactorsRisk FactorsEthnicityEthnicity
AgeAge
Family History / GeneticsFamily History / Genetics
The Epidemic: The Epidemic: Ethnic Groups at High Ethnic Groups at High
Risk for DMRisk for DM Aboriginal Aboriginal
LatinoLatino
South East AsianSouth East Asian
AsianAsian
African DescentAfrican Descent
77.1% of Canada’s immigrant 77.1% of Canada’s immigrant population are coming from population are coming from populations which from high risk populations which from high risk ethnic groupsethnic groups
7.3% 7.3% LatinosLatinos Central and South America, 7.3%Central and South America, 7.3%
57.0% Asian 57.0% Asian 12.8% African Decent12.8% African Decent
Caribbean and Bermuda, 5.5%Caribbean and Bermuda, 5.5% Africa, 7.3%Africa, 7.3%
Diabetes Risk Factors: Non-Modifiable Other High-risk Groups in Canada
REF: Statistics Canada, 1996 Census
Type 2 Diabetes is NOT a Type 2 Diabetes is NOT a Mild DiseaseMild Disease
Stroke
2- to 4-fold increase in cardiovascular mortality and stroke3
Cardiovascular Disease
8/10 diabetic patients die from CV events4
Diabetic Neuropathy
Leading cause of non-traumatic lower extremity amputations5
Diabetic Retinopathy
Leading cause of blindness in
working-age adults1
Diabetic Nephropathy
Leading cause of end-stage renal
disease2
1. Fong DS et al. Diabetes Care 2003; 26(Suppl 1):S99-S102. 2. Molitch ME et al. Diabetes Care 2003; 26(Suppl 1):S94-S98. 3. Kannel WB et al. Am J Heart 1990; 120:672-6. 4. Gray RP and Yudkin JS. In: Textbook of Diabetes. 1997. 5. Mayfield JA, et al. Diabetes Care 2003; 26(Suppl 1):S78-S79.
Diabetes Complications: Diabetes Complications: MacrovascularMacrovascular
DM is a major risk factor for cardiac DM is a major risk factor for cardiac diseasedisease
Acute MI occurs 15-20 years earlier Acute MI occurs 15-20 years earlier in those with DMin those with DM
Heart disease accounts for Heart disease accounts for approximately 50% of all deaths approximately 50% of all deaths among people with diabetes in among people with diabetes in industrialized countries industrialized countries
REF: Diabetes in Ontario, An ICES Practice Atlas, 2002
Several large epidemiological Several large epidemiological studies have found a strong studies have found a strong relationship between relationship between glucose level and subsequent coronary glucose level and subsequent coronary
events, even at ‘pre-diabetes’ levels events, even at ‘pre-diabetes’ levels (IGT and IFG)(IGT and IFG)
glucose levels that are only modestly glucose levels that are only modestly elevated place patients at risk. elevated place patients at risk.
REF: Coutiho M. et al Diabetes Care 1999;22:233-240.& DECODE Study Group. Arch Intern Med 2001;161:397-404.
Diabetes Complications:Diabetes Complications: MacrovascularMacrovascular
Diabetes Complications: Macrovascular
Relationship between FPG and CHD
REF: Coutinho et al. Diabetes Care 1999;22:233-40.
Metaregression - 20 prospective studies n = 95,783 - follow-up 12.4 yrsFPG > 6 mmol/L: RR 1.38 (1.06-1.67)
Fasting glucose (mmol/L)
Rel
ativ
e R
isk
2.5
2
1.5
14 5 6 7 8 9
Diabetes….Diabetes…. Is the leading cause of non traumatic Is the leading cause of non traumatic
amputationamputation Increases the risk of amputation by 20 Increases the risk of amputation by 20
foldfold those living in the north or in low income those living in the north or in low income
neighborhoods and those with poor access neighborhoods and those with poor access to physician services are at particular risk to physician services are at particular risk for amputation.for amputation.
REF: Diabetes in Ontario, An ICES Practice Atlas, 2002
Diabetes Complications: Diabetes Complications: MicrovascularMicrovascular – Amputation– Amputation
DiabetesDiabetes Is a leading cause of adult-onset Is a leading cause of adult-onset
blindnessblindness Prevalence of diabetic retinopathy is ~ Prevalence of diabetic retinopathy is ~
70% in persons with type 1 and 40% 70% in persons with type 1 and 40% with person with type 2 diabetes. with person with type 2 diabetes.
REF: Diabetes in Ontario, An ICES Practice Atlas, 2002
Diabetes Complications: Diabetes Complications: MicrovascularMicrovascular – Retinopathy– Retinopathy
Diabetes Diabetes Is the leading cause of ESRDIs the leading cause of ESRD Increases the risk of developing ESRD Increases the risk of developing ESRD
by up to 13-foldby up to 13-fold
Refs: Meltzer S, et al CMAJ 1998; 159 (8 suppl):S1-S29, &
Parchman ML, et al Medical Care 2002; 40(2):137-144.
Diabetes Complications: Diabetes Complications: MicrovascularMicrovascular - - NephropathyNephropathy
Prevention strategiesPrevention strategies
Primary PreventionPrimary Prevention Prevent diabetes through reduction of Prevent diabetes through reduction of
modifiable risk factors in general modifiable risk factors in general populationpopulation
Secondary PreventionSecondary Prevention Screening those at high-risk for diabetesScreening those at high-risk for diabetes
Tertiary PreventionTertiary Prevention Upon diagnosis of diabetes, prevention of Upon diagnosis of diabetes, prevention of
complications morbidity, and mortalitycomplications morbidity, and mortality
REF: Diabetes Blueprint
Primary Prevention Primary Prevention ModelModel
GoalGoal Reducing modifiable risk factors for diabetesReducing modifiable risk factors for diabetes
Target Target General population & high-risk groups General population & high-risk groups
MessagesMessages Healthy lifestyle choicesHealthy lifestyle choices
Current Delivery Models of Primary Current Delivery Models of Primary PreventionPrevention Population HealthPopulation Health Primary CarePrimary Care
REF: Health Canada
Primary Prevention Model: Primary Prevention Model: Population HealthPopulation Health – National – National
CDS
Health Canada
NADA
GoalGoal Early identification of those with Early identification of those with
dysglycemia dysglycemia Target Target
High-risk individuals and groups High-risk individuals and groups MessagesMessages
Diabetes awarenessDiabetes awareness Current delivery model of secondary Current delivery model of secondary
prevention relies on primary careprevention relies on primary care
Secondary PreventionSecondary Prevention
Secondary Prevention: Secondary Prevention: Is It Effective?Is It Effective?
Yes….Yes…. Patients diagnosed with IGT can be Patients diagnosed with IGT can be
prevented from progressing to type 2 prevented from progressing to type 2 diabetes diabetes 58% reduction with lifestyle changes (DPP, 58% reduction with lifestyle changes (DPP,
DPS) DPS) 30% reduction with medication (DPP, Stop 30% reduction with medication (DPP, Stop
NIDDM) NIDDM)
Tertiary Prevention: Tertiary Prevention: Is it Effective?Is it Effective?
Yes…Yes… Strong evidence for tertiary prevention Strong evidence for tertiary prevention
particularly for microvascular diseaseparticularly for microvascular disease DCCT, UKPDSDCCT, UKPDS
How to translate this evidence into How to translate this evidence into practice?practice?
Tertiary PreventionTertiary Prevention
GoalsGoals Glucose, blood pressure, and lipid Glucose, blood pressure, and lipid
control to reduce the development of control to reduce the development of complicationscomplications
Complication screening for early Complication screening for early identification and managementidentification and management
Why are Obesity and Type 2 DM
Increasing in Frequency? More sedentary lifestyles More sedentary lifestyles Worldwide changes in urbanization and nutritionWorldwide changes in urbanization and nutrition Aging population due to demographic growth rates Aging population due to demographic growth rates
(baby boomers) and increased life expectancy (baby boomers) and increased life expectancy
www.who.int and www.idf.org accessed March 16, 2006
19901985
1994
< 10%
< 10% - 14.9%
> 15%
No data
1996 1998
Source: Katzmarzyk PT, CMAJ Apr. 16, 2002; 166 (8)
Obesity by Province: BMI Obesity by Province: BMI 3030
ObesityObesity The most common metabolic condition in The most common metabolic condition in
industrialized nationsindustrialized nations Statistics Canada: 48% of Canadians Statistics Canada: 48% of Canadians
between ages 20-64 yr are overweight between ages 20-64 yr are overweight (BMI>25)(BMI>25)
Associated with dyslipidemia, impaired Associated with dyslipidemia, impaired glucose tolerance and insulin resistanceglucose tolerance and insulin resistance
Risk factor for developing metabolic Risk factor for developing metabolic syndrome, type 2 Dm, cardiovascular syndrome, type 2 Dm, cardiovascular diseasedisease
Huge economic costsHuge economic costs
Obesity in Canada: 1978/79 to 2004
Data from Canadian Community Health Survey www.statcan.ca/Daily/English/050706/d050706a.htm
Quick Facts:Quick Facts:
% of obese children increased from 3% to 8%
Among adults, the increase was even more dramatic: from 14% to 23%, a total of 5.5 million people
About 30% of baby boomers (aged 45 to 64) are obese
Canada’s Food guide to Canada’s Food guide to healthy eatinghealthy eating
Promote a diet with 30% or less Promote a diet with 30% or less energy from fat, 15-20% energy energy from fat, 15-20% energy from protein and 50-55% from from protein and 50-55% from complex carbohydratescomplex carbohydrates
Despite a decrease from 40% of Despite a decrease from 40% of energy from fat in U.S. diet in 1965 energy from fat in U.S. diet in 1965 to 34% in 1991, incidence of obesity to 34% in 1991, incidence of obesity increasedincreased
Why is it Important to Why is it Important to Recognize the Recognize the
Metabolic Syndrome?Metabolic Syndrome?A prevalent condition associated with:A prevalent condition associated with: Significantly increased CVD risksSignificantly increased CVD risks Significantly increased risks for type 2 diabetesSignificantly increased risks for type 2 diabetes
It is treatable and preventableIt is treatable and preventable
Clinical Features of the Clinical Features of the Metabolic SyndromeMetabolic Syndrome
Abdominal obesityAbdominal obesity HyperglycemiaHyperglycemia Atherogenic dyslipidemiaAtherogenic dyslipidemia HypertensionHypertension Proinflammatory stateProinflammatory state Prothrombotic stateProthrombotic state
IDF Classification of the IDF Classification of the Metabolic SyndromeMetabolic Syndrome
5.6 mmol/L 5.6 mmol/L Fasting glucoseFasting glucose
130 Syst. or diast. 130 Syst. or diast. 85 mm Hg or Rx 85 mm Hg or RxBlood pressureBlood pressure
1.10 1.10 WomenWomen
0.900.90 MenMen
1.71.7HDL cholesterolHDL cholesterol
Men Men Waist C.Waist C. WomenWomen
94 cm 94 cm (37 in)(37 in) 80 cm 80 cm (31.5 in)(31.5 in)
90 cm 90 cm (35 in)(35 in) 80 cm 80 cm (31.5 in)(31.5 in)
85 cm 85 cm (33 in)(33 in) 90 cm 90 cm (35 in)(35 in)
Central obesityCentral obesity Europids, Mid-eastEuropids, Mid-east S. Asians, ChineseS. Asians, Chinese JapaneseJapanese
Cut PointsCut Points
Plus any 2 of the following for diagnosis:Plus any 2 of the following for diagnosis:
Inadequate evidence to recommend routine measurement of insulin resistance (e.g., plasma insulin), proinflammatory state, or prothrombotic state in the diagnosis of the metabolic syndrome
TriglyceridesTriglycerides
Risk FactorsRisk Factors
Metabolic SyndromeMetabolic Syndrome
A common condition associated with A common condition associated with increased cardiovascular disease risksincreased cardiovascular disease risks
Treatment is aimed at lifestyle Treatment is aimed at lifestyle modification to achieve desirable body modification to achieve desirable body weight and reduce abdominal obesityweight and reduce abdominal obesity
Multiple medical therapy may be Multiple medical therapy may be required to achieve metabolic targets required to achieve metabolic targets (lipids, glucose and BP)(lipids, glucose and BP)
Lifestyle modification benefits Lifestyle modification benefits everyone!everyone!
Therapeutic Therapeutic strategies for the strategies for the management of management of type 2 diabetes.type 2 diabetes.
Targets for Metabolic Targets for Metabolic Control: Control:
Glucose ControlGlucose Control (2003 CDA (2003 CDA Guidelines)Guidelines)Normal Range Normal Range
(consider if (consider if can be can be achieved achieved safely)safely)
Target for Target for Most PatientsMost Patients
A1CA1C 6.06.0 7.07.0
PreprandialPreprandial 4.0 – 6.04.0 – 6.0 4.0 – 7.04.0 – 7.0
2 h 2 h PostprandialPostprandial 5.0 – 8.05.0 – 8.0 5.0 – 10.05.0 – 10.0
Risk categories and target lipid levels
III-9
Clinical assessment and initiation of nutrition and physical activity
A1C <9% A1C ≥9%
BMI ≥25 BMI <25
Metformin (first-line)TZD
SecretagogueInsulin
Acarbose
MetforminTZD
SecretagogueInsulin
Acarbose
2 agents:Metformin
TZDSecretagogue
InsulinAcarbose
Insulin
Achieve Target A1C Achieve Target A1C within 6within 6––12 Months12 Months
Timely adjustments/additions should be made to attain target A1C within 6–12 months.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2003;27(Suppl 2):S1–152.
Oral Medications Oral Medications to Treat Type 2 to Treat Type 2
DiabetesDiabetes
Oral Medications Oral Medications to Treat Type 2 to Treat Type 2
DiabetesDiabetes
Major Classes of Major Classes of MedicationsMedications
1. Drugs that sensitize 1. Drugs that sensitize the body to insulin the body to insulin and/or control hepatic and/or control hepatic glucose productionglucose production
2. Drugs that stimulate 2. Drugs that stimulate the pancreas to make the pancreas to make more insulinmore insulin
3. Drugs that slow the3. Drugs that slow the absorption of starchesabsorption of starches
ThiazolidinedioneThiazolidinedioness
BiguanidesBiguanides
SulfonylureasSulfonylureasMeglitinidesMeglitinides
Alpha-glucosidase Alpha-glucosidase inhibitorsinhibitors
ThiazolidinedionesThiazolidinediones Thiazolidinediones decrease insulin resistance by Thiazolidinediones decrease insulin resistance by
making muscle and adipose cells more sensitive to making muscle and adipose cells more sensitive to insulin. They also suppress hepatic glucose insulin. They also suppress hepatic glucose production.production.
EfficacyEfficacy Decrease fasting plasma glucose ~1.9-2.2 mmol/LDecrease fasting plasma glucose ~1.9-2.2 mmol/L Reduce A1C ~0.5-1.0%Reduce A1C ~0.5-1.0% 6 weeks for maximum effect6 weeks for maximum effect
Other EffectsOther Effects Weight gain, edema Weight gain, edema Hypoglycemia (if taken with insulin or agents that stimulate Hypoglycemia (if taken with insulin or agents that stimulate
insulin release)insulin release) Contraindicated in patients with abnormal liver function or Contraindicated in patients with abnormal liver function or
CHFCHF Improves HDL cholesterol and plasma triglycerides; usually Improves HDL cholesterol and plasma triglycerides; usually
LDL neutralLDL neutral Medications in this Class: pioglitazone (Actos), Medications in this Class: pioglitazone (Actos),
rosiglitazone (Avandia), rosiglitazone (Avandia),
BiguanidesBiguanides Biguanides decrease hepatic glucose production and Biguanides decrease hepatic glucose production and
increase insulin-mediated peripheral glucose uptake.increase insulin-mediated peripheral glucose uptake. EfficacyEfficacy
Decrease fasting plasma glucose 3.3-3.9 mmol/LDecrease fasting plasma glucose 3.3-3.9 mmol/L Reduce A1C 1.0-2.0%Reduce A1C 1.0-2.0%
Other EffectsOther Effects Diarrhea and abdominal discomfortDiarrhea and abdominal discomfort Risk of Lactic acidosis in those at risk (renal failure, CHF)Risk of Lactic acidosis in those at risk (renal failure, CHF) Cause small decrease in LDL cholesterol level and triglyceridesCause small decrease in LDL cholesterol level and triglycerides No specific effect on blood pressureNo specific effect on blood pressure No weight gain, with possible modest weight lossNo weight gain, with possible modest weight loss Contraindicated in patients with impaired renal function Contraindicated in patients with impaired renal function
(eGFR<33 ml/min)(eGFR<33 ml/min) Medications in this Class: metformin (Glucophage), Medications in this Class: metformin (Glucophage),
metformin hydrochloride extended release metformin hydrochloride extended release (Glumetza)(Glumetza)
SulfonylureasSulfonylureas Sulfonylureas increase endogenous insulin Sulfonylureas increase endogenous insulin
secretionsecretion EfficacyEfficacy
Decrease fasting plasma glucose 3.3-3.9 mmol/LDecrease fasting plasma glucose 3.3-3.9 mmol/L Reduce A1C by 1.0-2.0%Reduce A1C by 1.0-2.0%
Other EffectsOther Effects HypoglycemiaHypoglycemia Weight gain Weight gain No specific effect on plasma lipids or blood pressureNo specific effect on plasma lipids or blood pressure Generally the least expensive class of medicationGenerally the least expensive class of medication
Medications in this Class:Medications in this Class: glyburide (DiaBeta), glimepiride (Amaryl), gliclizide glyburide (DiaBeta), glimepiride (Amaryl), gliclizide
(Diamicron)(Diamicron)
MeglitinidesMeglitinides Meglitinides stimulate insulin secretion Meglitinides stimulate insulin secretion
(rapidly and for a short duration) in the (rapidly and for a short duration) in the presence of glucose.presence of glucose.
EfficacyEfficacy Decreases peak postprandial glucoseDecreases peak postprandial glucose Decreases plasma glucose 3.3-3.9 mmol/LDecreases plasma glucose 3.3-3.9 mmol/L Reduce A1C 1.0-2.0%Reduce A1C 1.0-2.0%
Other EffectsOther Effects Hypoglycemia (although may be less than with Hypoglycemia (although may be less than with
sulfonylureas if patient has a variable eating schedule)sulfonylureas if patient has a variable eating schedule) Weight gain Weight gain No significant effect on plasma lipid levelsNo significant effect on plasma lipid levels Safe at higher levels of serum Cr than sulfonylureasSafe at higher levels of serum Cr than sulfonylureas
Medications in this Class: repaglinide Medications in this Class: repaglinide (Gluconorm), nateglinide (Starlix)(Gluconorm), nateglinide (Starlix)
Alpha-glucosidase Alpha-glucosidase InhibitorsInhibitors Alpha-glucosidase inhibitors block the Alpha-glucosidase inhibitors block the
enzymes that digest starches in the small enzymes that digest starches in the small intestineintestine
EfficacyEfficacy Decrease peak postprandial glucose 2.2-2.8 mmol/LDecrease peak postprandial glucose 2.2-2.8 mmol/L Decrease fasting plasma glucose 1.4-1.7 mmol/LDecrease fasting plasma glucose 1.4-1.7 mmol/L Decrease A1C 0.5-1.0%Decrease A1C 0.5-1.0%
Other EffectsOther Effects Flatulence or abdominal discomfort Flatulence or abdominal discomfort No specific effect on lipids or blood pressureNo specific effect on lipids or blood pressure No weight gainNo weight gain Contraindicated in patients with inflammatory bowel Contraindicated in patients with inflammatory bowel
disease or cirrhosisdisease or cirrhosis Medications in this Class: acarbose Medications in this Class: acarbose
(Glucobay)(Glucobay)
Treatment of Type 2 Treatment of Type 2 DiabetesDiabetes
DiagnosisDiagnosis
Therapeutic Lifestyle ChangeTherapeutic Lifestyle Change
Combination Therapy - Oral Drug with InsulinCombination Therapy - Oral Drug with Insulin
Combination Therapy - Oral Drugs OnlyCombination Therapy - Oral Drugs Only
MonotherapyMonotherapy
Insulin TherapyInsulin Therapy
Normal Pancreatic Normal Pancreatic FunctionFunction
Meal Meal Meal
Bolus: At mealtime, insulin is rapidly released
in response to food.
Basal: Beta cells secrete small amounts of insulinthroughout the day.
Basal Insulin
Bolus Insulin
• Expected insulin changes during the day Expected insulin changes during the day for individuals with a healthy pancreasfor individuals with a healthy pancreas..
*Insulin effect images are theoretical representations and are not derived from clinical trial data.
Action Profiles of Bolus Action Profiles of Bolus & Basal Insulins& Basal Insulins
Pla
sm
a In
sulin
lev
els
HoursNote: action curves are approximations for illustrative purposes. Actual patient response will vary.
regular 6-10 hours
NPH 12–20 hours
lispro/aspart 4–6 hours
BASAL INSULINS
detemir ~ 6-23 hours (dose dependant)
glargine ~ 20-26 hours
Mayfield, JA.. et al, Amer. Fam. Phys.; Aug. 2004, 70(3): 491 Plank, J. et.al. Diabetes Care, May 2005; 28(5): 1107-12
BOLUS INSULINS
• Expected insulin changes during the day Expected insulin changes during the day • for individuals with a healthy pancreas.for individuals with a healthy pancreas.
*Insulin effect images are theoretical representations and are not derived from clinical trial data
Mayfield, JA. et al., Amer. Fam. Phys.; Aug. 2004, 70(3): 489-500
BID NPH and Regular BID NPH and Regular Insulin Therapy - Insulin Therapy -
Compared to Normal Compared to Normal PhysiologyPhysiology
Bolus needs: Regular
Basal needs: NPH
Meal Meal Meal
• Expected insulin changes during the day Expected insulin changes during the day • for individuals with a healthy pancreas.for individuals with a healthy pancreas.
*Insulin effect images are theoretical representations and are not derived from clinical trial data.
Multiple Daily Injections Multiple Daily Injections (MDI) – (MDI) –
Strive to Mimic Normal Strive to Mimic Normal PhysiologyPhysiology
MDI insulin therapy addresses:
Bolus needs: Lispro, Aspart Basal needs: Glargine, Detemir
Meal Meal Meal
Insulin RegimensInsulin RegimensType 2Type 2
Usually – a single bedtime injection Usually – a single bedtime injection of basal insulin added to OAD. of basal insulin added to OAD.
Occasionally - twice daily injections Occasionally - twice daily injections of basal insulin with OAD.of basal insulin with OAD.
Twice daily injection of “pre-mixed” Twice daily injection of “pre-mixed” insulin (split mix without mixing).insulin (split mix without mixing).
Intensive insulin – basal/bolusIntensive insulin – basal/bolus 40% basal/20% mealtime with each meal40% basal/20% mealtime with each meal
Case 1Case 1
Breakfast Lunch Dinner Bedtime
9.5 7.5 7.1 7.0
Is this patient well controlled? Does this patient require insulin?If “yes”… How would you start insulin here? How do you titrate the insulin dose? What do you do with the oral agents?
55 year old, 84 kg, BMI 29, T2DM 5 yrs, 55 year old, 84 kg, BMI 29, T2DM 5 yrs, A1C = 7.5% A1C = 7.5% On metformin, glyburide, TZD (thiazolidinedione)On metformin, glyburide, TZD (thiazolidinedione)
Case 1 - Bedtime InsulinCase 1 - Bedtime Insulin
Breakfast Lunch Dinner Bedtime
Start with 10 units1, or use 0.1- 0.2 units/kg and titrate2 Ex. 84 kg X 0.1 = 8 units OR 84 kg X 0.2 = 17 units Continue metformin, glyburide. Continuing TZD would be
off-label in Canada
NPH, Glargine or Detemir - 10 units
55 year old, 84 kg, BMI 29, T2DM 5 yrs, 55 year old, 84 kg, BMI 29, T2DM 5 yrs, A1C = A1C = 7.5% 7.5% On metformin, glyburide, TZDOn metformin, glyburide, TZD
- - -
1 Riddle et.al., Diabetes Care, 2003, 26(11):3080-862 CDA 2003 CPG, Can J Diabetes 27(Suppl 2):S135
Dosage Initiation & Dosage Initiation & Titration for Once-Daily Titration for Once-Daily
Insulin RegimensInsulin Regimens Initial dose of insulin at bedtime (Glargine, Detemir, Initial dose of insulin at bedtime (Glargine, Detemir,
NPH)NPH) - - Safe starting dose should equal fasting blood Safe starting dose should equal fasting blood
glucose glucose in mmol/L. in mmol/L. For example: Fasting glucose = 10 For example: Fasting glucose = 10 mmol/Lmmol/L Starting Insulin Dose = 10 unitsStarting Insulin Dose = 10 units
Self-adjustment of insulin dosesSelf-adjustment of insulin doses - Measure fasting glucose daily during first - Measure fasting glucose daily during first
weeks or weeks or months; after reaching target, months; after reaching target, frequency of testing can frequency of testing can reduce to once a weekreduce to once a week
-- If fasting glucose exceeds 5.5 mmol/L on three If fasting glucose exceeds 5.5 mmol/L on three consecutive FPG measurements, increase consecutive FPG measurements, increase
bedtime bedtime insulin dose by 2 units insulin dose by 2 units Yki-Jarvinen, H., Diabetes Care 2001, 24(4): 758-67
Hypoglycemia – Hypoglycemia – RecognitionRecognition
Hypoglycemia = development of symptoms or a plasma Hypoglycemia = development of symptoms or a plasma glucose <4.0 mmol/L.glucose <4.0 mmol/L.
Symptoms of hypoglycemiaSymptoms of hypoglycemia
AutonomicAutonomic NeuroglycopenicNeuroglycopenicTremblingTremblingPalpitationsPalpitationsSweatingSweatingAnxietyAnxiety
HungerHungerNauseaNauseaTinglingTingling
Difficulty Difficulty concentrating concentrating Vision changesVision changesDifficulty speakingDifficulty speakingHeadacheHeadacheDizzinessDizziness
ConfusionConfusionWeaknessWeaknessDrowsinessDrowsinessTirednessTiredness
Severity of hypoglycemiaSeverity of hypoglycemiaMild: Mild: Autonomic symptoms are present. The individual is Autonomic symptoms are present. The individual is able to self-treat.able to self-treat.Moderate: Moderate: Autonomic and neuroglycopenic symptoms are Autonomic and neuroglycopenic symptoms are present. The individual is able to self-treat.present. The individual is able to self-treat.Severe: Severe: Individual requires assistance of another person. Individual requires assistance of another person. Unconsciousness may occur. Plasma glucose is typically Unconsciousness may occur. Plasma glucose is typically <2.8 mmol/L. <2.8 mmol/L.
CDA 2003 CPG, Can J Diabetes 27(Suppl 2):S43
Type 2 Diabetes and Type 2 Diabetes and DyslipidemiaDyslipidemia
Dyslipidemic Profile in Type Dyslipidemic Profile in Type 2 Diabetes2 Diabetes
Type 2 diabetes is associated with a Type 2 diabetes is associated with a lipid profile that increases CV risk:lipid profile that increases CV risk:
Low levels of HDL cholesterolLow levels of HDL cholesterol Elevated triglyceridesElevated triglycerides Raised concentrations of free fatty acidsRaised concentrations of free fatty acids Increased small, dense, and more atherogenic Increased small, dense, and more atherogenic
LDL particlesLDL particles Total LDL levels remain relatively unchangedTotal LDL levels remain relatively unchanged Raised total cholesterol / HDL cholesterol ratioRaised total cholesterol / HDL cholesterol ratio
Pyorala K, et al. Diabetes Care. 1997;20:614-620.
Paolisso G, Howard BV. Diabet Med 1998;15:360-366. Haffner SM, et al. Diabetes Care. 1999;22:562-568.
LDL Atherogenicity in LDL Atherogenicity in Type 2 DiabetesType 2 Diabetes
Total LDL cholesterol concentrations Total LDL cholesterol concentrations similar to those in nondiabetic similar to those in nondiabetic controls, BUT…controls, BUT…
Important qualitative changes in LDLImportant qualitative changes in LDL Shift in LDL subfraction distribution to Shift in LDL subfraction distribution to
smaller denser particles (pattern B)smaller denser particles (pattern B) Increased susceptibility to oxidationIncreased susceptibility to oxidation Glycation of LDL apo BGlycation of LDL apo B
Adapted from Chait A, Bierman EL. Joslin's Diabetes Mellitus 13th ed. Philadelphia: Lea & Febiger; 1994:648-664.Haffner SM. Diabetes Care. 1998;2:160-178.
Reduce LDL-C to target for high risk patients Reduce LDL-C to target for high risk patients (< 2.0 mmol/L)(< 2.0 mmol/L)
Combinations of lipid-lowering medications can Combinations of lipid-lowering medications can and should be used to achieve lipid targetsand should be used to achieve lipid targets
Statin + cholesterol absorption inhibitorsStatin + cholesterol absorption inhibitors
Statin + fibratesStatin + fibrates
Statin + niacinStatin + niacin
Cholesterol absorption inhibitors + fibratesCholesterol absorption inhibitors + fibrates
Treatment optionsTreatment options
Vascular Protection Through Vascular Protection Through a a
Multifaceted ApproachMultifaceted Approach For ALL High-risk Patients with Diabetes • ACEI• ASA (clopidogrel if intolerance)• Lifestyle management: No smoking, healthy diet / weight, physical activity
Blood Pressure Control
Aim for BP < 130/80 mm Hg
If BP >130/80 mm Hg despite ACEI:Treat as per hypertension recommendations (CHEP/CHS)
Glycemic Control
Aim for A1C < 7.0%(< 6.0% if achievable safely)
If AIC > 7%: Treat as per glycemiarecommendations (CDA)
High CV risk
Renal Protection•Treat as per nephropathy recommendations (CDA)
Lipid Control
Adapted from Can J Diabetes. 2003;27:S58-S65.
When monotherapy fails to achieve lipid targets, the addition of a second drug from another class should be considered
Aim forLDL ≤ 2.0 andTC:HDL < 4.0
Smoking Cessation advice.
Diabetic Diabetic NephropathyNephropathy
Diabetic NephropathyDiabetic Nephropathy Over 40% of new cases of Over 40% of new cases of
end-stage renal disease end-stage renal disease (ESRD) are attributed to (ESRD) are attributed to diabetes. diabetes.
In 2001, 41,312 people with In 2001, 41,312 people with diabetes began treatment for diabetes began treatment for end-stage renal disease in end-stage renal disease in U.S.U.S.
In 2001, it cost $22.8 billion In 2001, it cost $22.8 billion in public and private funds to in public and private funds to treat patients with kidney treat patients with kidney failure.failure.
Minorities experience higher Minorities experience higher than average rates of than average rates of nephropathy and kidney nephropathy and kidney diseasedisease
Incidence of ESRD Resulting from Primary
Diseases (1998)
43%
23%
12%
3%
19%
Diabetes
Hypertension
Glomerulonephritis
Cystic Kidney
Other Causes
Screening for Diabetic Screening for Diabetic NephropathyNephropathy
Test When Normal Range
Blood Pressure1
Each office visit <130/80 mm/Hg
Urinary Albumin1
Type 2: Annually beginning at diagnosis Type 1: Annually, 5-years post-diagnosis
<30 mg/day 30 g/mgcreatinine
1American Diabetes Association: Nephropathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl.1): S79-S83, 2004
ACR </= 2.8 for womenACR </= 2.0 for men
Treatment of Diabetic Treatment of Diabetic NephropathyNephropathy
Hypertension Control -Hypertension Control - Goal: lower Goal: lower blood pressure to <130/80 mmHg blood pressure to <130/80 mmHg Antihypertensive agentsAntihypertensive agents
Angiotensin-converting enzyme (ACE) Angiotensin-converting enzyme (ACE) inhibitorsinhibitors
captopril, enalapril, lisinopril, benazepril, captopril, enalapril, lisinopril, benazepril, fosinopril, ramipril, quinapril, perindopril, fosinopril, ramipril, quinapril, perindopril, trandolapril, moexipriltrandolapril, moexipril
Angiotensin receptor blocker (ARB) therapy Angiotensin receptor blocker (ARB) therapy candesartan cilexetil, irbesartan, losartan candesartan cilexetil, irbesartan, losartan
potassium, telmisartan, valsartan, esprosartan potassium, telmisartan, valsartan, esprosartan
Beta-blockersBeta-blockers
Glycemic Control Glycemic Control Preprandial plasma glucose 90-130 mg/dlPreprandial plasma glucose 90-130 mg/dl A1C <7.0%A1C <7.0% Peak postprandial plasma glucose <180 Peak postprandial plasma glucose <180
mg/dlmg/dl Self-monitoring of blood glucose (SMBG)Self-monitoring of blood glucose (SMBG) Medical Nutrition TherapyMedical Nutrition Therapy
Restrict dietary protein to RDA of 0.8 Restrict dietary protein to RDA of 0.8 g/kg body weight per day g/kg body weight per day
Treatment of Diabetic Treatment of Diabetic Nephropathy (cont.)Nephropathy (cont.)
Treatment of Diabetic Treatment of Diabetic Nephropathy (cont.)Nephropathy (cont.)
Treatment of End-Stage Treatment of End-Stage Renal Disease (ESRD)Renal Disease (ESRD)
There are three primary treatment There are three primary treatment options for individuals who options for individuals who experience ESRD:experience ESRD:
1. Hemodialysis1. Hemodialysis
2. Peritoneal Dialysis2. Peritoneal Dialysis
3. Kidney Transplantation3. Kidney Transplantation
How Can You Prevent How Can You Prevent Diabetic Kidney Diabetic Kidney
Disease?Disease? Maintain blood pressure <130/80 Maintain blood pressure <130/80
mm/Hgmm/Hg Maintain preprandial plasma glucose 4-Maintain preprandial plasma glucose 4-
7 mmol/L7 mmol/L Maintain postprandial plasma glucose Maintain postprandial plasma glucose
<10 mmol/L<10 mmol/L Maintain A1C <7.0%Maintain A1C <7.0% Use ACE inhib or ARB if ACR is Use ACE inhib or ARB if ACR is
elevated even if normotensiveelevated even if normotensive Use antiplatelet therapyUse antiplatelet therapy
Diabetic Diabetic RetinopathyRetinopathy
Diabetic RetinopathyDiabetic Retinopathy
• Diabetic retinopathy is the most common cause of new cases of blindness among adults 20-74 years of age.
• During the first two decades of disease, nearly all patients with type 1 diabetes and over 60% of patients with type 2 diabetes have retinopathy
Risks of Diabetic Risks of Diabetic Retinopathy Related Retinopathy Related
Vision LossVision Loss Duration of diabetes diseaseDuration of diabetes disease type 1 patients experience a 25% rate of type 1 patients experience a 25% rate of
retinopathy after 5 years of disease, and 80% at retinopathy after 5 years of disease, and 80% at 15 years of disease15 years of disease11
Up to 21% of newly diagnosed type 2 patients Up to 21% of newly diagnosed type 2 patients have some degree of retinopathy at time of have some degree of retinopathy at time of diagnosisdiagnosis11
PubertyPuberty PregnancyPregnancy Lack of appropriate ophthalmic examinationLack of appropriate ophthalmic examination
1American Diabetes Association: Retinopathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl.1): S84-S87, 2004
Retinopathy ScreeningRetinopathy Screening Type 1 diabetes - screen within 3-5 Type 1 diabetes - screen within 3-5
years of diagnosis after age 10years of diagnosis after age 1011
Type 2 diabetes - screen at time of Type 2 diabetes - screen at time of diagnosisdiagnosis11
Pregnancy - women with preexisting Pregnancy - women with preexisting diabetes should be screened prior to diabetes should be screened prior to conception and during first trimesterconception and during first trimester11
Follow-up annually; less frequent Follow-up annually; less frequent exams (2-3 yrs) may be consideredexams (2-3 yrs) may be considered11
Examination Methods - Dilated indirect Examination Methods - Dilated indirect ophthalmoscopy coupled with ophthalmoscopy coupled with biomicroscopy and seven-standard field biomicroscopy and seven-standard field steroscopic 30° fundus photographysteroscopic 30° fundus photography11
1American Diabetes Association: Retinopathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl.1): S84-S87, 2004
Natural History of Natural History of Diabetic RetinopathyDiabetic Retinopathy
Mild nonproliferative Mild nonproliferative diabetic retinopathy diabetic retinopathy (NPDR)(NPDR)
Moderate NPDRModerate NPDR Severe NPDRSevere NPDR Very Severe NPDRVery Severe NPDR Proliferative diabetic Proliferative diabetic
retinopathy (PDR)retinopathy (PDR)
Diabetic Diabetic ketoacidosisketoacidosis
TYPE 1 Diabetes
10%
Beta cell destruction (usually autoimmune)
Low or absent
Required for survival
Often <30 (but can occur at any age)
Usually lean
Smaller
Acute, severe
Yes
No
Proportion of diabetes cases
Pathogenesis
Endogenous insulin secretion
Need for insulin therapy
Age of onset
Body habitus
Genetic component
Symptoms at onset
Ketoacidosis
Long-term complications present at dx?
TYPE 2 Diabetes
90%
Insulin resistance, relative insulin deficiency
Variable
Required in <50%, to improve control rather than for survival
Often >40
Often obese
Very large
Often mild, slow onset
Rare
Retinopathy ~20%, CVD relatively common
Diagnostic criteriaDiagnostic criteria
HyperglycemiaHyperglycemia Glucose >11.1 mmol/l; usually > 15 mmol/lGlucose >11.1 mmol/l; usually > 15 mmol/l
metabolic acidosis (increased anion gap)metabolic acidosis (increased anion gap) pH < 7.35pH < 7.35 decreased bicarbonate <15 (best estimation decreased bicarbonate <15 (best estimation
with venous)with venous) positive serum ketonespositive serum ketones
Urine ketones: may be absent in early stagesUrine ketones: may be absent in early stages
Insulin deficiencyInsulin deficiency
Decreased peripheral glucose Decreased peripheral glucose utilizationutilization
increased glucose productionincreased glucose production liver - gluconeogenesis (from liver - gluconeogenesis (from
aminoacids, glycerol), glycogenolysisaminoacids, glycerol), glycogenolysis increased ketogenesisincreased ketogenesis
increased lipolysis in adipocytes - increased lipolysis in adipocytes - provides free fatty acids for ketones and provides free fatty acids for ketones and glycerol for gluconeogenesisglycerol for gluconeogenesis
Clinical featuresClinical features
Hyperglycemia: thirst, polyuria, Hyperglycemia: thirst, polyuria, circulatory collapsecirculatory collapse
Ketosis: “acetone breath’Ketosis: “acetone breath’ Acidosis/ compensatory respiratory Acidosis/ compensatory respiratory
alkalosis: tachypneaalkalosis: tachypnea
DKA: Precipitating Causes
Consequences of DKAConsequences of DKA
HyperglycemiaHyperglycemia osmotic diuresisosmotic diuresis
dehydrationdehydration loss of K, Na, HCO3 in urineloss of K, Na, HCO3 in urine
hyperosmolar state hyperosmolar state increase free water into blood increase free water into blood hyponatremia, hyponatremia,
cerebral dehydration cerebral dehydration decreased level of decreased level of consciousnessconsciousness
acidosisacidosis compensatory respiratory alkalosiscompensatory respiratory alkalosis K shifts (hyperkalemia)K shifts (hyperkalemia)
Laboratory Calculations Laboratory Calculations for diagnosis and for diagnosis and
treatmenttreatment Serum osmolalitySerum osmolality 2(Na + K) + glucose +BUN2(Na + K) + glucose +BUN
serum Naserum Na for each 3-4 mmol/l increase in glucose, Na for each 3-4 mmol/l increase in glucose, Na
should decrease by 1should decrease by 1 anion gapanion gap
Na -(Cl+HCO3)Na -(Cl+HCO3) compensation for metabolic acidosiscompensation for metabolic acidosis If suspect other causes for acidosis; If suspect other causes for acidosis;
meausre serum lactate and salicylatemeausre serum lactate and salicylate
TreatmentTreatment
GOAL: GOAL: replace volume lossreplace volume loss stop ketone productionstop ketone production replace K loss (K initially high but falls replace K loss (K initially high but falls
rapidly with treatment)rapidly with treatment) lower serum glucoselower serum glucose
**Need to correct INSULIN DEFICIENCYNeed to correct INSULIN DEFICIENCY
*Look for precipitating cause and treat*Look for precipitating cause and treat
FluidFluid NS 1L per hour first 2 hours, then 1L over 4 hrsNS 1L per hour first 2 hours, then 1L over 4 hrs NS until glucose < 15 NS until glucose < 15 then D5/NS or D5 depending if still replacing then D5/NS or D5 depending if still replacing
volumevolume insulininsulin
intravenousintravenous 50 units regular in 500 normal saline (0.1U/ml)50 units regular in 500 normal saline (0.1U/ml) Bolus 0.1 unit per kg body weight (IM/IV)Bolus 0.1 unit per kg body weight (IM/IV) Infusion 0.1 unit/kg/hourInfusion 0.1 unit/kg/hour Glucoscans q1h, adjust IV rate and IV D5Glucoscans q1h, adjust IV rate and IV D5* Do not stop insulin infusion until acidosis/ AG * Do not stop insulin infusion until acidosis/ AG
correctedcorrected bicarbonate generally avoidedbicarbonate generally avoided potassiumpotassium
start when K 4.5-5.0, 20 mmol/Lstart when K 4.5-5.0, 20 mmol/L
Hyperosmolar non-Hyperosmolar non-ketotic stateketotic state
Severe hyperglycemia generally in DM Severe hyperglycemia generally in DM type 2type 2
dehydrationdehydration serum hyperosmolalityserum hyperosmolality lack of significant ketosis (still some lack of significant ketosis (still some
circulating insulin)circulating insulin)
* takes less insulin to prevent ketosis than * takes less insulin to prevent ketosis than to stop hyperglycemiato stop hyperglycemia
Stressor - increased insulin Stressor - increased insulin resistanceresistance
relative insulin deficiencyrelative insulin deficiency increased glucose production, increased glucose production,
decreased utilizationdecreased utilization reduced renal excretion of glucose reduced renal excretion of glucose
secondary to renal disease, aging secondary to renal disease, aging kidneyskidneys
Treatment of HONKTreatment of HONK
Correct increased serum osmolality Correct increased serum osmolality Blood glucose will fall in response to Blood glucose will fall in response to
fluid repletionfluid repletion If Na>155 mmol/L, start 0.45% NS If Na>155 mmol/L, start 0.45% NS
as initial fluidas initial fluid Insulin infusion only if persistent Insulin infusion only if persistent
hyperglycemia after fluid repletehyperglycemia after fluid replete
ThyroidThyroid
Average weight 20 gms (~0.7 ounces)
Thyroid GlandThyroid GlandThyroid GlandThyroid Gland
Thyroid Hormone ReviewThyroid Hormone Review
Tetraiodothyronine Tetraiodothyronine (T4)(T4) and and triiodothyronine triiodothyronine (T3)(T3) released from thyroid released from thyroid gland in ratio gland in ratio 20:120:1
T3 is the active form T3 is the active form or thyroid hormoneor thyroid hormone
20% of T3 from 20% of T3 from thyroid gland, 80% thyroid gland, 80% from extra-thyroidal from extra-thyroidal conversion by conversion by 5’deiodinase enzyme5’deiodinase enzyme
Thyroid Review cont…Thyroid Review cont…
T4 converted to T3 by T4 converted to T3 by 5’deiodinase5’deiodinase enzyme in enzyme in target tissuestarget tissues
5’deiodinase also converts 5’deiodinase also converts T4 to T4 to rT3 (inactive form)rT3 (inactive form)
rT3 production rT3 production upregulated (at the upregulated (at the expense of T3) in acute or expense of T3) in acute or chronic illnesschronic illness
Thyroid hormones exert a Thyroid hormones exert a variety of effects including variety of effects including inotropic and chronotropicinotropic and chronotropic effects on the heart (direct effects on the heart (direct and permissive via and permissive via upregulation of B-upregulation of B-adrenergic receptors), adrenergic receptors), vasodilation,vasodilation, increased increased heat production.heat production.
Review: Hypothalamic-Review: Hypothalamic-Pituitary AxisPituitary Axis
Review: Hypothalamic-Review: Hypothalamic-Pituitary AxisPituitary Axis
What can go wrong?What can go wrong?
FunctionalFunctional HypothyroidismHypothyroidism
HyperthyroidismHyperthyroidism
StructuralStructural NodulesNodules
CancerCancer
BothBoth
Can exacerbate pre-Can exacerbate pre-existing medical existing medical conditions.conditions.
FatigueFatigue Slow heart rateSlow heart rate ConstipationConstipation Menstrual Menstrual
IrregularitiesIrregularities Dry Skin, Coarse Hair Dry Skin, Coarse Hair Cold IntoleranceCold Intolerance
HypothyroidismHypothyroidism
Signs of HypothyroidismSigns of Hypothyroidism Pseudomyotonic reflexes (95%)Pseudomyotonic reflexes (95%)
Hypothermia or cold skin (83%)Hypothermia or cold skin (83%)
Skin changes (79%) – nonpitting waxy dry edema, Skin changes (79%) – nonpitting waxy dry edema, dependant edema (30%)dependant edema (30%)
Coarse hair (76%), loss of axillary and pubic hair Coarse hair (76%), loss of axillary and pubic hair (30%), loss of scalp and facial hair (18%)(30%), loss of scalp and facial hair (18%)
Pallor (24%)Pallor (24%)
Abdominal distension (18%)Abdominal distension (18%)
Goiter (16%)Goiter (16%)
Pericardial effusion, dull facial expression, Pericardial effusion, dull facial expression, unsteady gait, husky voice, periorbital puffiness, unsteady gait, husky voice, periorbital puffiness, bradycardia, narrow pulse pressure, macroglossia, bradycardia, narrow pulse pressure, macroglossia, CTS, thyroidectomy scarCTS, thyroidectomy scar
LabsLabs – macrocytic anemia, hyponatremia, – macrocytic anemia, hyponatremia, elevated CPK, AST, LDH dyslipidemia, low FT4elevated CPK, AST, LDH dyslipidemia, low FT4
LEVOTHYROXINE
•T4 preparation exact chemical structure of human
thyroxine
• stable, cheap, widely available
• one of the most commonly prescribed drugs
•half life is ~ 7 days
DOSAGE ADJUSTMENT
• evaluate clinical response
• measure TSH ~ 6 weeks after change in dose
• adjust dose by 0.025 mg (0.012 mg)
• once TSH is in target range, repeat annually
RISKS OF OVER TREATMENTWITH THYROID HORMONES
• induce symptoms of hyperthyroidism
• may accelerate bone loss in those at risk
• exacerbate angina
• risk of atrial fibrillation
• increased heart rate and myocardial contractility•Important to keep the T3 level in the target range
THYROID HORMONE REPLACEMENTIN PREGNANCY
• requirements can increase by 25 - 50%
• must monitor TSH every 8 weeks and and 6 weeks after dosage adjustment
• target TSH in normal range
• post pregnancy - requirements return to pre-pregnancy dose
THYROIDITIS
Thyroiditis with pain and tenderness:
• acute infectious (rare)
• subacute granulomatous thyroiditis (common, viral)
SUBACUTE GRANULOMATISTHYROIDITIS
• subacute thyroiditis or DeQuervains’ thyroiditis, likely viral
• three phases: hyperthyroid,hypothyroidrecovery phase
• treatment: NSAID or prednisone, • -blocker for hyperthyroid symptoms L-T4 not usually necessary
POST-PARTUM THYROIDITIS
• lymphocytic thyroiditis up to 1 year post-partum, usually 6 weeks after delivery
• usually mild phases of hyper/hypothyroidism
• anti-thyroid peroxidase antibodies elevated
• usually resolves but can recur after future pregnancies
HYPERTHYROIDISM
Symptoms Signs
Nervousness Restlessness
Heat intolerance Warm, moist skin
Insomnia Tremor
Sweating Diffuse goitre
Diarrhea Bruit
OTHER OTHER MANIFESTATIONSMANIFESTATIONS
dermopathydermopathy
onycholysisonycholysis
gynecomastiagynecomastia
palmar erythemapalmar erythema
spider angiomataspider angiomata
myopathymyopathy
periodic periodic paralysisparalysis
vitiligovitiligo
HYPERTHYROIDISM -MOST COMMON CAUSES
• Graves’ Disease
• Toxic nodular goitresolitary nodular or multinodular
• hyperthyroid phase of subacute thyroiditis
• excessive administration of thyroid hormone
HYPERTHYROIDISM -UNCOMMON CAUSES
• choriocarcinoma or hydatidiform moles (HCG)• thyroid carcinoma
toxic carcinomatous nodule from widespread metastasis
• struma ovarii• associated with acromegaly• related to polyostotic fibrous dysplasia• induced by iodine• TSH-producing pituitary adenoma• T3 toxicosis
LABORATORY TESTING
Graves’ Toxic Toxic Thyroiditisnodular nodule
FT4
FT3
TSH
RAIU
ETIOLOGY OF GRAVESDISEASE
• autoimmune disorder
• TSI bind to hTSH-R
TSHor Ab
GRAVES’ DISEASE
• most common cause of hyperthyroidism
• females 4: males 1
• autoimmune disorder
• thyroid stimulating immunoglobulin (TSI)
• genetic factors
AUTOIMMUNE DISEASES ASSOCIATED WITHGRAVES’ AND HASHIMOTO’S DISEASES
Graves’ disease
• Hashimoto’s thyroiditis• Pernicious anemia• Addison’s disease• Diabetes mellitus• Vitiligo• Myasthenia gravis• Rheumatoid arthritis• Idiopathic thrombocytopenic purpura
Hashimoto’s thyroiditis
• Graves’ disease• Pernicious anemia• Sjögren’s syndrome• Addison’s disease• Rheumatoid arthritis
GRAVES’ DISEASE -MANIFESTATIONS
• hyperthyroidism
• ophthalmopathy
• “pretibial myxedema”
Graves DermopathyGraves Dermopathy
Accumulation of Accumulation of polysaccharides – polysaccharides – glycosglycosaminoglycanaminoglycanss
Usually on anterior Usually on anterior tibiatibia
Can be painful, Can be painful, usually has red usually has red appearanceappearance
Graves’ OphthalmopathyGraves’ Ophthalmopathy
Thyroid stareThyroid stare chemosischemosis ProptosisProptosis Improves with Improves with
treatment of treatment of hyperthyroidismhyperthyroidism
GRAVES’ DISEASE - TREATMENT
• antithyroid drugs propylthiouracil methimazole
• radioactive iodine Complications:
recurrence hypothyroidism
• subtotal thyroidectomy Complications:
recurrence hypothyroidism vocal cord palsy hypoparathyroidism
Hyperthyroidism and pregnancy
•Start propylthiouraci if needed, (methimazole is second choice).
•Target free T4 and free T3 to the upper range of normal
•Refer to Endocrinology
•Ensure women with history of Graves’ disease inform their doctor’s with each pregnancy.
Subclinical Subclinical HyperthyroidismHyperthyroidism
40 y.o woman c/o fullness in neck, otherwise will40 y.o woman c/o fullness in neck, otherwise will
TSH is <0.1 mU/LTSH is <0.1 mU/L fT4 is 18 pmol/L, fT3 is 4.8 pmol/LfT4 is 18 pmol/L, fT3 is 4.8 pmol/L no palpable nodule, slight goitreno palpable nodule, slight goitre
Do you need to do more? Only if becomes Do you need to do more? Only if becomes symptomatic or is high risk for atrial fib. or symptomatic or is high risk for atrial fib. or osteoporosisosteoporosis
Subclinical Hyperthyroidism
• Increase risk of atrial fibrillation
• May have mild symptoms of hyperthyroidism
• increased risk of bone loss
• Treat if symptoms or has other risk factors for
AF or osteoporosis
• Most cases of subclinical hyperthyroidism
resolve within 1 year without treatment
THYROID NODULAR DISEASETHYROID NODULAR DISEASE
Prevalence of thyroid nodulesPrevalence of thyroid nodules 4% on palpation (most are 2cm)4% on palpation (most are 2cm) 67% by ultrasound67% by ultrasound 50% by autopsy50% by autopsy ~30,000 palpable nodules found ~30,000 palpable nodules found
annuallyannually Rarely malignant, ~5%Rarely malignant, ~5%
CAUSES OF THYROID NODULES
• Common causes: colloid nodule (nodular goitre) cyst benign neoplasm papillary carcinoma
Uncommon causes: granulomatous thyroiditis infections cancer: follicular, medullary, anaplastic, metastatic (breast, renal, GI), lymphoma
Thyroid Nodule or Nodules
Fine Needle Aspiration Biopsy
Benign solid Thyroid Nodule
Observation for 1 Year
Thyroid Ultrasonography
Size Decreased Size Unchanged Size Increased
Continue Observation Fine NeedleAspiration Biopsy
Benign Nodule Malignant orSuspicious Nodule
L-Thyroxine SuppressiveTherapy for 1 Year
Surgery
Thyroid Ultrasonography
Size decreased or
unchanged
Size Increased
Surgery
Continue L-ThyroxineTherapy
Decision making for treatment of patients with benign thyroid nodules
Castro, M. R. et. al. Ann Intern Med 2005;142:926-931
Ultrasonography-guided fine-needle aspiration with needle tip accurately placed in the nodule
TREATMENT OF THYROIDNODULES
Toxic Nodule
• antithyroid drugs
• radioactive iodine
• surgery
• Ethanol injection
Nontoxic Nodule
• observation
• thyroxine suppression
• surgery
Thyroid Cancer Thyroid Cancer UpdateUpdate
OutlineOutline
What types?What types?
How common?How common?
Treat?Treat?
Follow-up?Follow-up?
Question 1Question 1
Thyroid cancer is the most rapidly Thyroid cancer is the most rapidly increasing cancer among Canadians increasing cancer among Canadians age 20-44.age 20-44.
TrueTrue
FalseFalse
Question 2Question 2
One is considered “cured” after One is considered “cured” after being disease-free for 10 years being disease-free for 10 years and no further follow-up is and no further follow-up is required.required.
TrueTrue
FalseFalse
Thyroid CancerThyroid Cancer
Differentiated Differentiated Papillary (83%)Papillary (83%) Follicular (9%)Follicular (9%)
Medullary (2%)Medullary (2%)
AnaplasticAnaplastic
LymphomaLymphoma
“Cancer Care Ontario: Cancer in Young Adults in Canada, May 2006
How common?How common?
~3400 cases in Canada in 2006 ~3400 cases in Canada in 2006
33rdrd most common in young adults most common in young adults
Most rapidly growing Most rapidly growing
2-3 times more prevalent in women2-3 times more prevalent in women
“Cancer Care Ontario: Cancer in Young Adults in Canada, May 2006
“Cancer Care Ontario: Cancer in Young Adults in Canada, May 2006
Prognosis = good!Prognosis = good!
Age at diagnosis Age at diagnosis (<45 yrs)(<45 yrs)
Tumour size Tumour size
RecurrenceRecurrence
MetastasesMetastases
Pathologic featuresPathologic features
Cumulative RecurrenceCumulative Recurrenceand Cancer Death After Initial and Cancer Death After Initial
TherapyTherapy
Mazzaferri. Am J Med. 1994; 97:418–428.
4040
Patients at risk Patients at risk (n)(n)
13551355 10751075 568568 185185 1010
Years after initial therapy
00 1010 2020 3030 4040
Cum
ulat
ive
per
cent
00
1010
2020
3030
RecurrenceRecurrence
Cancer deathCancer death
At 30 years:
Recurrence 30%
Cancer death 8%
Therefore …Therefore …
Thyroid cancer prevalence is increasing Thyroid cancer prevalence is increasing
– particularly in young adults– particularly in young adults
Prognosis is generally goodPrognosis is generally good
Death from thyroid cancer is uncommonDeath from thyroid cancer is uncommon
Recurrence can happen even years after Recurrence can happen even years after
diagnosis diagnosis
TreatmentTreatment
TreatmentTreatment
1. THYROIDECTOMY1. THYROIDECTOMY
To remove the cancer and the To remove the cancer and the
rest of the thyroidrest of the thyroid
To provide information about the To provide information about the
cancer (size etc)cancer (size etc)
TreatmentTreatment2.2. RADIOIODINE REMNANT ABLATIONRADIOIODINE REMNANT ABLATION
Iodine is taken up by thyroid cellsIodine is taken up by thyroid cells
Radioiodine in large dose will destroy any Radioiodine in large dose will destroy any
remaining thyroid cells (normal and cancer)remaining thyroid cells (normal and cancer)
Works better when cells are “hungry” for Works better when cells are “hungry” for
iodineiodine
Must have a high TSH (means hypothyroid)Must have a high TSH (means hypothyroid)
Withdrawal of hormone is usual for treatmentWithdrawal of hormone is usual for treatment
Whole body scan 1 week laterWhole body scan 1 week later
TreatmentTreatment
3.3. THYROID REPLACEMENT (Thyroxine)THYROID REPLACEMENT (Thyroxine)
To replace missing thyroid hormoneTo replace missing thyroid hormone
Give a little “extra” to push down TSH Give a little “extra” to push down TSH
to not stimulate any remaining cells to not stimulate any remaining cells
(thyroid hormone suppression therapy)(thyroid hormone suppression therapy)
TreatmentTreatment
3. THYROID REPLACEMENT3. THYROID REPLACEMENT
Target TSH to <0.5 mIU/L for mostTarget TSH to <0.5 mIU/L for most
May consider TSH 0.3 – 2 long term May consider TSH 0.3 – 2 long term
in some casesin some cases
Thyroid CancerThyroid Cancer
Ensure suppressed TSHEnsure suppressed TSH Follow thyroglobulin as tumor Follow thyroglobulin as tumor
markermarker Periodic CXR, US neck Periodic CXR, US neck Stimulated thyroglobulin levels Stimulated thyroglobulin levels raise TSH by hypothyroidism or raise TSH by hypothyroidism or
ThyrogenThyrogen (rhTSH injection) (rhTSH injection) Iodine body scans (not always used)Iodine body scans (not always used)
Question 1Question 1
Thyroid cancer is the most rapidly Thyroid cancer is the most rapidly increasing cancer among Canadians increasing cancer among Canadians age 20-44.age 20-44.
TrueTrue
FalseFalse
Question 2Question 2
One is considered “cured” after One is considered “cured” after being disease-free for 10 years being disease-free for 10 years and no further follow-up is and no further follow-up is required.required.
TrueTrue
FalseFalse
Thank you!Thank you!